预约演示
更新于：2025-05-24
Lasmiditan Succinate
拉米地坦
更新于：2025-05-24
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2019-10-11), |
最高研发阶段(中国)无进展 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C42H42F6N6O8 |
InChIKeyMSOIHUHNGPOCTH-UHFFFAOYSA-N |
CAS号439239-92-6 |
关联
39
项与 拉米地坦 相关的临床试验NCT06267664
Real-world Effectiveness and Tolerability of Triptans-Ditans-Gepants (TRIDIGEP): an International Prospective Multicentric Cohort Study
CTR20233131
拉米地坦片人体生物等效性研究预试验
NCT05903040
Effectiveness and Tolerability of Lasmiditan as Acute Migraine Treatment: a Prospective, Multicentric, Cohort Study
100 项与 拉米地坦 相关的临床结果
登录后查看更多信息
100 项与 拉米地坦 相关的转化医学
登录后查看更多信息
100 项与 拉米地坦 相关的专利（医药）
登录后查看更多信息
229
项与 拉米地坦 相关的文献（医药）2025-06-01Pain and Therapy
The Relationship Between Treatment Satisfaction and Medication Understanding Among Patients Taking a Novel Oral Pain Reliever: A Questionnaire-Based Cross-Sectional Study
Article
作者: Yamamoto, Shuhei ; Yonemoto, Takashi ; Takahashi, Makio ; Seki, Haruhiko ; Akahane, Maiko ; Kodama, Sho
INTRODUCTION:
Patient satisfaction is important in pain management. Satisfaction with prescribed pain relievers and continued use of these drugs may be affected by a patient's understanding of their efficacy and safety. We investigated the association between patients' satisfaction and understanding of their prescribed medication for three oral pain relievers (lasmiditan, mirogabalin, and tramadol) that recently became available in Japan.
METHODS:
This questionnaire-based, cross-sectional study included adult patients taking these oral pain relievers after April 2023. The primary endpoint was overall satisfaction (five-point rating) and the secondary endpoint was overall understanding (five-point rating) of the oral pain relievers.
RESULTS:
In total, 328 patients (lasmiditan, 36.9%; mirogabalin, 55.5%, tramadol, 8.8%; four patients had been prescribed more than one medication) were included, and 71.6% of patients reported high satisfaction (score 4, 5) with their oral pain relievers (lasmiditan, 62.0%; mirogabalin, 76.1%; tramadol, 85.2%). The proportion of patients in the total population who reported a high understanding (score 4, 5) of their oral pain relievers was 68.0% (lasmiditan, 77.7%; mirogabalin, 63.3%; tramadol, 55.6%). In the total population and the lasmiditan and mirogabalin subgroups, the patient satisfaction level was significantly associated with scores on medication understanding (Cochran-Armitage test, p < 0.0001 for all). Discontinuation rates were higher in patients who were unsatisfied with their treatment than those who were satisfied (38.7% and 9.8%, respectively).
CONCLUSION:
This study showed that a higher level of understanding of oral pain relievers is associated with higher satisfaction, which may be associated with lower discontinuation rates.
CLINICAL TRIAL REGISTRATION:
UMIN000052629.
2025-05-04Expert Opinion On Drug Safety
Safety profile of lasmiditan: a retrospective post-marketing pharmacovigilance study based on the real-world data of FAERS database
Article
作者: Zhang, Hongrui ; Zhang, Shuohan ; Jiang, Cheng ; Wan, Xiaochen
BACKGROUND:
Lasmiditan offers a promising option for the treatment of migraines, particularly for individuals with cardiovascular concerns. It is crucial to gather comprehensive safety information of lasmiditan through large-scale post market monitoring.
RESEARCH DESIGN AND METHODS:
This study assessed the safety profile of lasmiditan based on real-world data of FDA Adverse Event Reporting System (FAERS) database. Four disproportionality analysis methods were applied to mining the significant signals. The differences in adverse event signals among different subgroups were investigated concerning race, sex, age, weight, dose, and concomitant drug.
RESULTS:
A total of 820 reports and 1,661 adverse events with lasmiditan as the primary suspected drug were identified. Two new adverse event signals related to nervous system disorders emerged. Females and males were more likely to develop paresthesia and dizziness, respectively. Most common adverse events were more likely to occur in the elderly patients and at high doses.
CONCLUSIONS:
It is essential to be vigilant about the relation of potential nervous system disorders with lasmiditan. The importance of heightened clinical vigilance regarding paresthesia in females and dizziness in males was underscored. Additionally, it is advised to administer a lower initial dose for elderly patients.
2025-04-01Pain and Therapy
Lasmiditan and Different Triptans in Menstrual Migraine: A Bayesian Network Meta-analysis
Review
作者: Gu, Jingyu ; Li, Jian ; Song, Zhaoming ; Yang, Chen ; Chen, Zhouqing ; Guo, Yanao ; Wang, Zhong ; Qu, Ruisi
INTRODUCTION:
Menstrual migraine (MM) is a common subtype of migraine that greatly affects a woman's quality of life. A number of different drugs are used to treat menstrual migraine, but it is not known which is more effective.
METHODS:
In this study, we searched all randomized controlled trials that satisfied the inclusion and exclusion criteria up to December 2023 on PubMed, Embase and Cochrane Library using a suitable search strategy. We constructed a suitable network model for analysis after evaluating the heterogeneity among the included direct, indirect and pooled evidence. Odds ratio (OR) and corresponding 95% confidence intervals (CI) were used as valid indicators for this network meta-analysis.
RESULTS:
In the Bayesian network model we constructed, we found that lasmiditan (vs. placebo OR, 14; 95% CI 3.1-100) was better than rizatriptan (vs. placebo OR, 1.9; 95% CI 1.2-3.3) in terms of the rate of sustained freedom from pain. There was no statistically significant difference between lasmiditan and different triptans in terms of the rate of being pain-free at 2 h (2-h pain-free) and the rate of pain relief at 2 h (2-h pain relief). Regarding safety, the probability of adverse events was significantly higher for rizatriptan (OR, 2.7; 95% CI 1.1-7.3) than for placebo.
CONCLUSION:
In terms of treatment efficacy for MM, lasmiditan was not worse than different triptans and was even better than some of the triptans in the rate of sustained freedom from pain. As an emerging treatment, lasmiditan is promising for the treatment of MM. However, more research needs to be carried out because of the lack of safety analysis for lasmiditan.
100 项与 拉米地坦 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 偏头痛 | 美国 | 2019-10-11 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 无先兆偏头痛 | 临床3期 | 美国 | 2020-06-15 | |
| 无先兆偏头痛 | 临床3期 | 日本 | 2020-06-15 | |
| 无先兆偏头痛 | 临床3期 | 比利时 | 2020-06-15 | |
| 无先兆偏头痛 | 临床3期 | 法国 | 2020-06-15 | |
| 无先兆偏头痛 | 临床3期 | 德国 | 2020-06-15 | |
| 无先兆偏头痛 | 临床3期 | 印度 | 2020-06-15 | |
| 无先兆偏头痛 | 临床3期 | 意大利 | 2020-06-15 | |
| 无先兆偏头痛 | 临床3期 | 墨西哥 | 2020-06-15 | |
| 无先兆偏头痛 | 临床3期 | 荷兰 | 2020-06-15 | |
| 无先兆偏头痛 | 临床3期 | 波多黎各 | 2020-06-15 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 55 | 網糧淵選顧築廠襯觸鹽(簾廠選醖簾獵簾網鬱構) = Adverse events were reported in 53.1% of attacks, predominantly as dizziness ( n = 11), fatigue ( n = 8) and paraesthesia ( n = 6) 願範醖蓋醖願廠鑰築築 (簾壓蓋餘壓遞襯鬱觸齋 ) | 积极 | 2024-06-28 | |||
临床1期 | - | 97 | (150 mg Dabigatran Etexilate (Part 1 Period 1)) | 鏇壓廠糧衊齋齋鏇襯選(選觸鹹獵獵範築築廠獵) = 獵鬱鹹鑰網衊窪襯憲願 遞窪製醖憲憲夢觸鑰廠 (衊糧顧簾淵鑰夢糧鹽獵, 55) 更多 | - | 2024-02-01 | |
(150 mg Dabigatran Etexilate + 200 mg Lasmiditan (Part 1 Period 2)) | 鏇壓廠糧衊齋齋鏇襯選(選觸鹹獵獵範築築廠獵) = 顧膚範襯鬱觸壓願齋選 遞窪製醖憲憲夢觸鑰廠 (衊糧顧簾淵鑰夢糧鹽獵, 51) 更多 | ||||||
临床1期 | 47 | 鹽鹽糧鹹繭獵顧構襯觸(壓網選築餘遞夢觸齋獵) = 繭襯鹽選艱鹹餘淵餘製 獵鏇製淵醖夢膚餘鏇襯 (簾繭齋齋鹹鏇醖窪簾膚, 43) 更多 | - | 2023-03-23 | |||
临床2期 | 846 | 構願顧膚觸淵選簾壓願(鏇蓋窪齋鑰鏇餘鏇憲簾) = 鏇選夢膚觸壓衊遞選醖 壓遞淵築憲鏇醖構淵鏇 (選選鹹鏇積窪鏇衊顧鏇 ) | 积极 | 2022-09-22 | |||
選衊觸鏇選淵構蓋繭糧(繭獵淵糧觸襯觸繭餘網) = 網淵夢鹽夢鏇觸糧鹽憲 夢範鹽鏇網鏇衊鏇簾齋 (範觸醖壓窪窪鹽糧夢鹹 ) 更多 | |||||||
临床3期 | 281 | 簾簾鹽糧觸積膚鑰築窪(獵膚艱艱顧遞夢願壓簾) = no study drug-related treatment emergent serious adverse events (TESAEs) were reported 蓋願遞鹹齋襯淵糧願壓 (齋壓淵觸範鏇膚鏇衊餘 ) 更多 | 积极 | 2022-09-17 | |||
临床2/3期 | - | 網製艱窪獵襯衊齋淵膚(衊膚蓋衊艱糧憲繭獵觸) = A common TEAE (CTEAE) was defined as occurring in ≥ 2% in the overall population. Central nervous system (CNS)-CTEAEs were based on Medical Dictionary for Regulatory Activities. 範鬱廠醖鹽鑰構鹹襯觸 (醖獵網選齋醖選艱觸淵 ) 更多 | - | 2022-07-02 | |||
Placebo | |||||||
临床2期 | 846 | 衊衊構窪齋齋觸夢選糧(醖餘製構築廠築網觸餘) = 積齋繭選窪衊衊鹹鏇夢 願鹹膚淵鹹醖廠齋艱憲 (糧襯窪繭膚憲鏇構築艱 ) | 积极 | 2022-06-24 | |||
Placebo | 衊衊構窪齋齋觸夢選糧(醖餘製構築廠築網觸餘) = 蓋簾鑰齋網鹹醖齋窪積 願鹹膚淵鹹醖廠齋艱憲 (糧襯窪繭膚憲鏇構築艱 ) | ||||||
临床3期 | 3,177 | 繭衊糧鏇觸積壓願憲遞(糧蓋願廠遞夢獵鹹淵衊) = Cardiovascular events were not reported in the elderly population during the treatment-emergent period or intermediate period 構糧餘構鬱範願構壓廠 (範夢網廠壓憲餘構醖製 ) 更多 | - | 2021-08-06 | |||
Placebo | |||||||
临床3期 | 1,633 | Placebo+Lasmiditan (200 mg Lasmiditan) | 製遞獵簾網繭醖願醖艱 = 蓋壓範糧獵鑰網鑰選範 遞鹽選夢構鏇構醖範醖 (齋壓鑰糧觸構遞觸醖獵, 構餘鏇艱選齋窪齋蓋鏇 ~ 簾積蓋齋鑰鑰餘範願鬱) 更多 | - | 2021-07-02 | ||
Placebo+Lasmiditan (100 Milligram (mg) Lasmiditan) | 遞築網簾簾壓膚構鹹範(齋遞顧廠糧廠衊願糧夢) = 獵醖鏇膚網簾顧憲築齋 糧構築構遞醖構鬱鹹襯 (夢淵獵壓餘齋夢願獵廠, 淵鏇艱積網夢壓範鹹鑰 ~ 淵構糧構鹹膚淵廠繭簾) 更多 | ||||||
临床1期 | - | 36 | (100 mg Lasmiditan) | 蓋鬱醖糧製餘願艱範網(鑰鏇餘築蓋廠膚觸齋獵) = 製夢遞餘醖鏇構願鹽糧 觸鏇顧鹽艱齋糧壓衊醖 (廠製鏇獵夢範齋鹽觸淵, 34) 更多 | - | 2021-07-01 | |
(200 mg Lasmiditan) | 蓋鬱醖糧製餘願艱範網(鑰鏇餘築蓋廠膚觸齋獵) = 築遞憲願夢觸糧壓製願 觸鏇顧鹽艱齋糧壓衊醖 (廠製鏇獵夢範齋鹽觸淵, 34) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用